**Crabb et al**

**Systematic Review Search Strings**

**Results summary table**

|  |  |  |
| --- | --- | --- |
| **Database** | **Date** | **Results** |
| MEDLINE (Ovid) | 20/04/2023 | 53 |
| Embase (Ovid) | 20/04/2023 | 162 |
| Cochrane Library (Wiley) | 20/04/2023 | 38 (all in CENTRAL) |
| ClinicalTrials.gov (2 iterative searches due to size of search box) | 20/04/2023 | 28 (9 and 19) |
| TOTAL |  | 273 |
| TOTAL after removing duplicates |  | 247 |

**Search strings**

**Ovid MEDLINE(R) ALL**1946 to April 19, 2023

|  |  |  |
| --- | --- | --- |
| **#** | **Searches** | **Results** |
| 1 | exp Urologic Neoplasms/ | 151665 |
| 2 | exp Urinary Bladder Neoplasms/ | 61967 |
| 3 | Carcinoma, Transitional Cell/ | 21047 |
| 4 | "transitional cell".ti,ab,kf. | 11516 |
| 5 | ((bladder or urotheli\*) adj4 (cancer\* or neoplasm\* or tumo#r\* or malignan\* or carcino\*)).ti,ab,kf. | 70991 |
| 6 | 1 or 2 or 3 or 4 or 5 | 174178 |
| 7 | "Poly(ADP-ribose) Polymerase Inhibitors"/ | 5469 |
| 8 | ((PARP or "poly(adp-ribose) polymerase" or "poly(adp-ribosylation)" or "polyADP-ribose polymerase" or "polyADP-ribosylation") adj2 inhibitor\*).ti,ab,kf. | 7356 |
| 9 | (atamparib or cep9722 or "cep 9722" or fuzuloparib or fluzoparib or airuiyi or niraparib or zejula or olaparib or lynparza or ino1001 or "ino 1001" or pamiparib or rucaparib or rubraca or senaparib or talazoparib or talzenna or veliparib).ti,ab,kf. | 3337 |
| 10 | 7 or 8 or 9 | 9976 |
| 11 | 6 and 10 | 87 |
| 12 | randomized controlled trial.pt. | 591095 |
| 13 | controlled clinical trial.pt. | 95275 |
| 14 | randomi?ed.ab. | 716842 |
| 15 | placebo.ab. | 237514 |
| 16 | dt.fs. | 2583118 |
| 17 | randomly.ab. | 406482 |
| 18 | trial.ab. | 644553 |
| 19 | groups.ab. | 2505487 |
| 20 | 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 | 5655006 |
| 21 | exp animals/ not humans.sh. | 5114512 |
| 22 | 20 not 21 | 4935103 |
| 23 | 11 and 22 | 53 |
| 24 | limit 23 to english language | **53** |

**Embase Classic+Embase**1947 to 2023 April 19

|  |  |  |
| --- | --- | --- |
| **#** | **Searches** | **Results** |
| 1 | exp urinary tract cancer/ | 249438 |
| 2 | exp bladder cancer/ | 88514 |
| 3 | exp transitional cell carcinoma/ | 36881 |
| 4 | ((bladder or urotheli\*) adj4 (cancer\* or neoplasm\* or tumo#r\* or malignan\* or carcino\*)).ti,ab,kf. | 105978 |
| 5 | "transitional cell".ti,ab,kf. | 15268 |
| 6 | 1 or 2 or 3 or 4 or 5 | 275133 |
| 7 | exp nicotinamide adenine dinucleotide adenosine diphosphate ribosyltransferase inhibitor/ | 22374 |
| 8 | ((PARP or "poly(adp-ribose) polymerase" or "poly(adp-ribosylation)" or "polyADP-ribose polymerase" or "polyADP-ribosylation") adj2 inhibitor\*).ti,ab,kf. | 13536 |
| 9 | (atamparib or cep9722 or "cep 9722" or fuzuloparib or fluzoparib or airuiyi or niraparib or zejula or olaparib or lynparza or ino1001 or "ino 1001" or pamiparib or rucaparib or rubraca or senaparib or talazoparib or talzenna or veliparib).ti,ab,kf. | 7651 |
| 10 | 7 or 8 or 9 | 24733 |
| 11 | 6 and 10 | 892 |
| 12 | Clinical Trial/ | 1094317 |
| 13 | Randomized Controlled Trial/ | 782855 |
| 14 | controlled clinical trial/ | 469366 |
| 15 | multicenter study/ | 374248 |
| 16 | Phase 3 clinical trial/ | 69086 |
| 17 | Phase 4 clinical trial/ | 5402 |
| 18 | exp RANDOMIZATION/ | 99460 |
| 19 | Single Blind Procedure/ | 51505 |
| 20 | Double Blind Procedure/ | 212016 |
| 21 | Crossover Procedure/ | 75262 |
| 22 | PLACEBO/ | 412407 |
| 23 | randomi?ed controlled trial$.tw. | 323298 |
| 24 | rct.tw. | 53261 |
| 25 | (random$ adj2 allocat$).tw. | 54612 |
| 26 | single blind$.tw. | 31675 |
| 27 | double blind$.tw. | 249810 |
| 28 | ((treble or triple) adj blind$).tw. | 1885 |
| 29 | placebo$.tw. | 371891 |
| 30 | Prospective Study/ | 871929 |
| 31 | or/12-30 | 2962761 |
| 32 | Case Study/ | 107077 |
| 33 | case report.tw. | 555956 |
| 34 | abstract report/ or letter/ | 1312132 |
| 35 | Editorial.pt. | 772313 |
| 36 | Letter.pt. | 1299371 |
| 37 | Note.pt. | 935487 |
| 38 | or/32-37 | 3745145 |
| 39 | 31 not 38 | 2821067 |
| 40 | 11 and 39 | 181 |
| 41 | (conference abstract\* or conference review or conference paper or conference proceeding).db,pt,su. | 5523528 |
| 42 | limit 41 to yr="2020 -Current" | 920278 |
| 43 | 41 not 42 | 4603250 |
| 44 | 40 not 43 | 162 |
| 45 | limit 44 to english language | **162** |

**Cochrane Library (for CENTRAL)**

Search Name: PARP inhibitors for bladder cancer

Date Run: 20/04/2023 12:26:18

ID Search Hits

#1 MeSH descriptor: [Urologic Neoplasms] explode all trees 3667

#2 MeSH descriptor: [Urinary Bladder Neoplasms] explode all trees 1969

#3 MeSH descriptor: [Carcinoma, Transitional Cell] this term only 735

#4 ("transitional cell"):ti,ab,kw 1544

#5 ((bladder or urotheli\*) near/4 (cancer\* or neoplasm\* or tumo#r\* or malignan\* or carcino\*)):ti,ab,kw 5411

#6 #1 or #2 or #3 or #4 or #5 7134

#7 MeSH descriptor: [Poly(ADP-ribose) Polymerase Inhibitors] this term only 146

#8 ((PARP or "poly(adp-ribose) polymerase" or "poly(adp-ribosylation)" or "polyADP-ribose polymerase" or "polyADP-ribosylation") near/2 inhibitor\*):ti,ab,kw 859

#9 (atamparib or cep9722 or "cep 9722" or fuzuloparib or fluzoparib or airuiyi or niraparib or zejula or olaparib or lynparza or ino1001 or "ino 1001" or pamiparib or rucaparib or rubraca or senaparib or talazoparib or talzenna or veliparib):ti,ab,kw 1557

#10 #7 or #8 or #9 1685

#11 #6 and #10 **38**

**ClinicalTrials.gov 19/04/2023**

**9** Studies found for: PARP OR poly ADP-ribose OR polyadp-ribose | urothelial OR urinary OR bladder

**19** Studies found for: atamparib OR cep9722 OR "cep 99722" OR fuzuloparib OR fluzoparib OR airuiyi OR niraparib OR zejula OR olaparib OR lynparza OR ino1001 OR "ino 1001" OR pamiparib OR rucaparib OR rubraca OR senaparib OR talazoparib OR talzenna OR veliparib | urothelial OR urinary OR bladder

Manually deduplicated: **20** results